Spyre Therapeutics, Inc. Price & Performance (SYRE)

Egle Therapeutics presented new preclinical results at the AACR 2025 meeting, highlighting lead candidates EGL-001 and EGL-002. Both fusion antibodies demonstrated selective depletion of tumor-infiltrating regulatory T cells, showing strong anti-tumor activity in animal models. EGL-001 is now in early human trials, aiming to boost immunotherapy effectiveness.12

Recent corporate actions saw several companies delisted or merged, including Enzo Biochem, Syra Health, and MoneyLion. Shareholders in Paragon 28 and Patterson Companies received cash payouts, while others faced stock liquidations. These changes reflect ongoing consolidation and restructuring across multiple sectors, impacting investor portfolios and market liquidity.34

Spyre Therapeutics, formerly Aeglea BioTherapeutics, is progressing with its IBD drug candidates, including SPY001 and SPY002. Despite negative earnings ratios, analysts project significant upside for the stock. The company’s focus on novel antibody therapies positions it as a key player in the inflammatory bowel disease treatment landscape.56